Clinical Trials Browser

Uterine Cervical Dysplasia × pembrolizumab × 90 days × Clear all

NCT04712851 2026-03-10

Pembrolizumab for the Treatment of Cervical Intraepithelial Neoplasia

Phase 2 Recruiting

Uterine Cervical Dysplasia